"Filgrastim" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
| Descriptor ID |
D000069585
|
| MeSH Number(s) |
D12.644.276.374.410.240.350.500 D12.776.395.240.200.500 D12.776.467.374.410.240.350.500 D23.529.374.410.240.350.500
|
| Concept/Terms |
Filgrastim- Filgrastim
- G-CSF Recombinant, Human Methionyl
- G CSF Recombinant, Human Methionyl
- Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor
- Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
- R-metHuG-CSF
- R metHuG CSF
Zarxio- Zarxio
- Filgrastim-Sandoz
- Filgrastim Sandoz
- FilgrastimSandoz
- Filgrastim-Sndz
- Filgrastim Sndz
|
Below are MeSH descriptors whose meaning is more general than "Filgrastim".
Below are MeSH descriptors whose meaning is more specific than "Filgrastim".
This graph shows the total number of publications written about "Filgrastim" by people in this website by year, and whether "Filgrastim" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Filgrastim" by people in Profiles.
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
-
Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
-
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
-
Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 05 01; 18(5):e168-72.
-
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012 Nov; 47(11):1403-8.
-
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
-
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer. 2010 Oct 01; 10(5):367-72.
-
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.